Loading...
Printed on 7/19/2026
For informational purposes only. This is not medical advice.
QUICKI (Quantitative Insulin Sensitivity Check Index) is a fasting surrogate marker of insulin sensitivity calculated from fasting glucose and fasting insulin. Compared with HOMA-IR, QUICKI inversely scales with insulin resistance, so lower values generally suggest greater insulin resistance.
Formula: QUICKI = 1 / (log10(Fasting Insulin) + log10(Fasting Glucose))
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
Collect a venous blood sample after a true 8–12 hour fast (water only). Both serum insulin and plasma glucose must be drawn from the same sample. Fasting conditions are critical — even a small meal or caloric beverage will spike insulin and invalidate the result. Ensure the patient has not received any exogenous insulin within the past 24 hours.
Input fasting serum insulin (in mcU/mL or μIU/mL) and fasting plasma glucose (in mg/dL). The calculator applies the QUICKI formula: 1 / [log₁₀(insulin) + log₁₀(glucose)]. The logarithmic transformation normalizes the typically right-skewed distribution of insulin values, improving the linearity of the insulin sensitivity estimate.
Results are interpreted using published threshold values: QUICKI above 0.339 indicates normal insulin sensitivity; 0.302–0.339 suggests impaired insulin sensitivity (consistent with metabolic syndrome or prediabetes); below 0.302 indicates insulin resistance in the diabetes range. Higher QUICKI values always indicate better insulin sensitivity — the scale is inverse to HOMA-IR.
Clinical researchers, metabolic investigators
QUICKI is widely used in epidemiological and intervention studies to quantify insulin sensitivity across populations. Its log-linear scaling makes it more amenable to parametric statistical analysis than HOMA-IR in some research designs, particularly when comparing treatment arms in metabolic intervention trials.
Endocrinologists, gynecologists, reproductive specialists
Insulin resistance is central to the pathophysiology of PCOS, present in 50–70% of affected women regardless of BMI. Serial QUICKI measurements can track improvement in insulin sensitivity with metformin therapy, weight loss, or lifestyle modification programs, providing objective evidence of metabolic response to treatment.
Primary care, cardiologists, preventive medicine
In patients with central obesity, dyslipidemia, and hypertension fulfilling metabolic syndrome criteria, QUICKI provides a quantitative measure of underlying insulin resistance beyond the qualitative ATP III or IDF diagnostic categories. Serial values over years document metabolic trajectory.
Diabetologists, endocrinologists
QUICKI can identify insulin resistance in individuals whose fasting glucose is still in the normal range (prediabetes is defined as fasting glucose 100–125 mg/dL). Reduced QUICKI in normoglycemic individuals predicts future progression to type 2 diabetes and helps identify candidates for intensive lifestyle intervention.
Sports medicine, obesity medicine, lifestyle medicine
Tracking QUICKI before and after dietary changes, aerobic exercise programs, or weight loss interventions provides an objective biomarker of metabolic improvement independent of HbA1c changes. Serial QUICKI captures early improvements in insulin signaling that precede changes in glucose metrics.
Pediatric endocrinologists, pediatric researchers
QUICKI is widely used in pediatric metabolic studies, particularly in childhood obesity and adolescent metabolic syndrome research. Pediatric reference ranges differ from adult values due to pubertal insulin resistance, and QUICKI's normalized scale facilitates cross-age comparisons within longitudinal studies.
QUICKI scales inversely to HOMA-IR: a higher number is always better. This intuitive directionality (like other 'index' measures — higher sensitivity index = better) makes QUICKI conceptually easier to communicate to patients during lifestyle counseling compared to HOMA-IR where a higher number means worse.
QUICKI and HOMA-IR are mathematically related — they both use only fasting insulin and fasting glucose, just arranged differently. You can calculate both from a single fasting blood draw at no extra cost. Reporting both in a metabolic evaluation provides a comprehensive picture and allows comparison with published studies using either metric.
Several validation studies have shown QUICKI correlates marginally better with the euglycemic hyperinsulinemic clamp (the gold standard for insulin sensitivity) than HOMA-IR in obese individuals, particularly at very high insulin levels. The logarithmic transformation handles extreme hyperinsulinemia better than the linear HOMA-IR formula.
An 8–12 hour fast is required for both QUICKI and HOMA-IR. Even a small caloric intake (including cream in coffee) acutely raises insulin levels, producing a falsely low QUICKI value. Verify fasting status verbally and note it in the medical record. Lipemic samples may also indicate a non-fasted state.
The commonly cited QUICKI threshold of 0.339 was derived from predominantly White Western populations. South Asian individuals have been shown to have significant insulin resistance at QUICKI values that would appear normal by Western cutoffs. Population-appropriate reference ranges should be used when available.
The real utility of QUICKI in clinical practice is longitudinal tracking — not single measurements. A patient improving their QUICKI from 0.310 to 0.330 after a 6-month lifestyle program demonstrates meaningful metabolic improvement even if neither value crosses the 0.339 threshold. Serial trends are more informative than single cross-sectional values.
Published validation data from Katz et al. (2000) demonstrated QUICKI correlation with the euglycemic hyperinsulinemic clamp at r = 0.78, slightly higher than HOMA-IR's correlation in the same dataset. Both are strong surrogate markers, making either appropriate for clinical and research use depending on which has been validated in the specific population being studied.
QUICKI is invalid in type 1 diabetes or any condition of absolute insulin deficiency because fasting insulin levels are near zero or undetectable, making the logarithm undefined or producing artifactual results. In patients on insulin therapy for T2DM, endogenous insulin cannot be separated from exogenous insulin, also invalidating the formula.
Like HOMA-IR, QUICKI is most appropriate for comparing groups, tracking populations over time, and epidemiological research. Individual values have wide confidence intervals — a single QUICKI measurement in one patient should not be used as the sole basis for a diagnosis of insulin resistance without clinical context and other metabolic markers.
Fasting insulin immunoassays are not standardized across laboratories. The same blood sample sent to different labs may yield different numerical insulin values depending on whether the assay detects proinsulin and split proinsulin. This means absolute QUICKI values are only comparable within the same laboratory method — use the same lab for serial measurements in a given patient.
QUICKI was developed by Katz et al. (J Clin Endocrinol Metab 2000) as a simpler surrogate index of insulin sensitivity with improved statistical properties compared to HOMA-IR. Correlation with the euglycemic hyperinsulinemic clamp (reference standard) was reported at r = 0.78. The threshold of 0.339 for normal insulin sensitivity was derived from NHANES population data. QUICKI and HOMA-IR have been shown to produce equivalent results for population-level insulin resistance studies (Rabasa-Lhoret et al., 2003). Pediatric reference ranges established in multiple cohort studies including the Bogalusa Heart Study.
Lower QUICKI values generally reflect lower insulin sensitivity and may indicate higher insulin resistance.
Use QUICKI in metabolic risk assessment when fasting insulin and fasting glucose are available, especially for trend tracking over time.
Reference cutoffs vary across populations and assays. QUICKI is not a stand-alone diagnostic test and should be interpreted in clinical context.
For related assessments, see HOMA-IR, HbA1c Converter and TyG Index.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Estimate insulin resistance using fasting glucose and fasting insulin with the HOMA-IR equation.
OpenEndocrinologyConvert HbA1c to estimated average glucose (eAG): 6%=126 mg/dL, 7%=154, 8%=183, 9%=212. ADA 2026 target <7% for most adults with diabetes. Shows both mg/dL and mmol/L.
OpenCardiologyCalculate the Triglyceride-Glucose (TyG) Index from fasting triglycerides and fasting glucose to assess insulin resistance patterns.
Open